UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):December 18, 2015
Biota Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-35285 | 59-1212264 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
| | |
2500 Northwinds Parkway, Suite 100 Alpharetta, GA | 30009 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (678)221-3350
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item8.01Other Events
On December 18, 2015, Biota Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the initiation of a Phase 1 multiple ascending dose trial to evaluate the safety and pharmacokinetics of BTA585. A copy of the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 | Press release dated December 18, 2015. |
| | |
| | |
| | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Biota Pharmaceuticals, Inc. |
| | |
Date: December 18, 2015 | /s/ Joseph M Patti |
| | Name: | Joseph M Patti |
| | Title: | Chief Executive Officer and President |
| | | (Duly Authorized Officer) |
EXHIBIT INDEX
Exhibit Number | | Description |
99.1 | | Press release dated December 18, 2015. |
